The Translational Neuro-Oncology Laboratories aim to discover the cellular, molecular, and mathematical basis underlying the growth patterns of malignant brain tumors (glioma, GBM), and the interactions between cancer cells and the tumor microenvironment. Investigators in the Translational Neuro-Oncology Laboratories are also developing new immunotherapies for primary and metastatic brain cancer. Research efforts range from basic immunobiologic mechanisms to translational immune-therapeutics.
Pioneering work from the Translational Neuro-Oncology Laboratories has led to an FDA-approved Phase I clinical trial for malignant brain cancer that is ongoing within the U-M Department of Neurosurgery. Learn more about this clinical trial at michmed.org/zBLLq.